US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ImageneBio, Inc.

6.91

+0.06000.88%

Post-market: 6.910.00000.00%16:10 EST

Volume:18.47K

Turnover:129.92K

Market Cap:77.27M

PE:-0.79

High:7.21

Open:6.95

Low:6.87

Close:6.85

52wk High:18.70

52wk Low:5.70

Shares:11.18M

Float Shares:6.20M

Volume Ratio:0.44

T/O Rate:0.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-8.7700

EPS(LYR):-0.1236

ROE:--

ROA:--

PB:0.55

PE(LYR):-55.90

Loading ...

Overview Company News Filings

American Tungsten Announces Strong Initial Drill Results at IMA Mine in Idaho

Press Release: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

American Tungsten Expands Underground Drilling at Historic IMA Mine in Idaho

Joseph Slattery Spends US$96k On ImageneBio Stock

Simply Wall St.

Director Joseph P. Slattery Reports Acquisition of ImageneBio Inc. Common Shares

ImageneBio Chief Medical Officer Yufang Lu Resigns

Top Korean Securities Firms' Drive Toward Risky Corporate Financing a Capitalization Risk, S&P Says

MT Newswires Live

ImageneBio Coverage Assumed by Wedbush at Underperform

ImageneBio assumed at Underperform from Neutral at Wedbush

Imagenebio Inc : Wedbush Assumes Coverage With Underperform Rating; Price Target $2

THOMSON REUTERS

Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target

MT Newswires Live

ImageneBio Q3 EPS $(2.91) Misses $(1.28) Estimate

ImageneBio reports Q3 cash position of $142.6 million and increased R&D expenses

Imagenebio Inc- Qtrly Loss per Share $2.91

THOMSON REUTERS

Press Release: ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

Demand for Income Remains Strong

ImageneBio Inc. Files Initial Beneficial Ownership Statement for Director Joseph P. Slattery

ImageneBio Inc expected to post a loss of $1.28 a share - Earnings Preview

Brazilian forestry industry intensifies investment in genetics, R&D, AI to address climate risks

ImageneBio Inc. to Participate in Stifel Healthcare Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMA\",,,,,undefined,":{"symbol":"IMA","market":"US","secType":"STK","nameCN":"ImageneBio, Inc.","latestPrice":6.91,"timestamp":1771016400000,"preClose":6.85,"halted":0,"volume":18471,"hourTrading":{"tag":"盘后","latestPrice":6.91,"preClose":6.91,"latestTime":"16:10 EST","volume":1,"amount":6.91,"timestamp":1771017004811,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.008759124087591314,"floatShares":6199299,"shares":11181700,"eps":-8.77,"marketStatus":"Market Closed","change":0.06,"latestTime":"02-13 16:00:00 EST","open":6.95,"high":7.21,"low":6.87,"amount":129922.189,"amplitude":0.049635,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.77,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"listingDate":1616731200000,"exchange":"NASDAQ","adjPreClose":6.85,"postHourTrading":{"tag":"盘后","latestPrice":6.91,"preClose":6.91,"latestTime":"16:10 EST","volume":1,"amount":6.91,"timestamp":1771017004811,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.43697451242146856},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMA\",,,,,undefined,":{"symbol":"IMA","floatShares":6199299,"roa":"--","roe":"--","lyrEps":-0.123616,"volumeRatio":0.43697451242146856,"shares":11181700,"dividePrice":0,"high":7.21,"amplitude":0.049635,"preClose":6.85,"low":6.87,"week52Low":5.7,"pbRate":"0.55","psRate":"96.58","week52High":18.696,"institutionHeld":0,"latestPrice":6.91,"eps":-8.77,"divideRate":0,"volume":18471,"delay":0,"ttmEps":-8.77,"open":6.95,"prevYearClose":6.9,"prevWeekClose":6.91,"prevMonthClose":7.51,"prevQuarterClose":6.9,"fiveDayClose":6.91,"twentyDayClose":6.58,"sixtyDayClose":7.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"IMA","fiscalQuarterEnding":"2025/09","expectedEps":-1.47,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-2.91},{"market":"US","date":"2025-07-28","symbol":"IMA","defaultRemindTime":1753709400000,"type":"split","dateTimestamp":1753675200000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2025-07-24","symbol":"IMA","fiscalQuarterEnding":"2025/06","expectedEps":-0.14,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1753329600000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2025-05-08","symbol":"IMA","fiscalQuarterEnding":"2025/03","expectedEps":-0.21,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.18},{"market":"US","date":"2025-03-06","symbol":"IMA","fiscalQuarterEnding":"2024/12","expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741237200000,"reportTimeType":"pre","actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0,"hold":0,"sell":0,"strongSell":0.3333,"meanLabel":"BUY","meanPercent":0,"analysts":3,"updateTime":1764133200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IMA","date":"2026-02-12","current":-0.787913,"percent":0.695313,"low":-8.134224,"twenty":-4.49394,"median":-3.91361,"eighty":-1.667098,"high":-1.428237,"avg":-3.50678,"sd":2.008775,"marketCap":74769711},"quantilePoints":[{"date":"2025-08-15","current":-8.134224,"twenty":-8.112228,"median":-8.06823,"eighty":-8.016532,"marketCap":165376899},{"date":"2025-08-22","current":-7.269609,"twenty":-8.089126,"median":-7.938985,"eighty":-7.265478,"marketCap":157437913},{"date":"2025-08-29","current":-6.949498,"twenty":-8.071529,"median":-7.347055,"eighty":-7.207651,"marketCap":150505278},{"date":"2025-09-05","current":-4.362798,"twenty":-8.06823,"median":-7.269609,"eighty":-7.002161,"marketCap":94485111},{"date":"2025-09-12","current":-4.750028,"twenty":-7.913135,"median":-7.165056,"eighty":-4.777909,"marketCap":102871364},{"date":"2025-09-19","current":-4.311167,"twenty":-7.809737,"median":-7.03727,"eighty":-4.615789,"marketCap":93366944},{"date":"2025-09-26","current":-4.016872,"twenty":-7.532127,"median":-6.908193,"eighty":-4.311167,"marketCap":86993392},{"date":"2025-10-03","current":-4.460896,"twenty":-7.322272,"median":-4.750028,"eighty":-4.238884,"marketCap":96609628},{"date":"2025-10-10","current":-4.24921,"twenty":-7.284065,"median":-4.672583,"eighty":-4.255406,"marketCap":92025144},{"date":"2025-10-17","current":-3.918773,"twenty":-7.257217,"median":-4.460896,"eighty":-4.122198,"marketCap":84868875},{"date":"2025-10-24","current":-3.815512,"twenty":-7.248956,"median":-4.418301,"eighty":-4.002415,"marketCap":82632541},{"date":"2025-10-31","current":-4.336982,"twenty":-7.148276,"median":-4.396358,"eighty":-4.069535,"marketCap":93926028},{"date":"2025-11-07","current":-4.331819,"twenty":-7.057922,"median":-4.378287,"eighty":-4.107742,"marketCap":93814211},{"date":"2025-11-14","current":-4.300841,"twenty":-7.039335,"median":-4.362798,"eighty":-4.109807,"marketCap":93143311},{"date":"2025-11-21","current":-1.760672,"twenty":-6.984607,"median":-4.334401,"eighty":-3.978665,"marketCap":76154335},{"date":"2025-11-28","current":-1.69911,"twenty":-6.937107,"median":-4.311167,"eighty":-3.941491,"marketCap":73491596},{"date":"2025-12-05","current":-1.66956,"twenty":-6.910259,"median":-4.306004,"eighty":-3.874371,"marketCap":72213481},{"date":"2025-12-12","current":-1.593223,"twenty":-6.057319,"median":-4.275025,"eighty":-1.94191,"marketCap":68911685},{"date":"2025-12-19","current":-1.524274,"twenty":-4.777909,"median":-4.254373,"eighty":-1.770522,"marketCap":65929417},{"date":"2025-12-26","current":-1.44055,"twenty":-4.748995,"median":-4.244047,"eighty":-1.699602,"marketCap":62308092},{"date":"2026-01-02","current":-1.69911,"twenty":-4.744865,"median":-4.207906,"eighty":-1.69911,"marketCap":73491596},{"date":"2026-01-09","current":-1.686797,"twenty":-4.71905,"median":-4.130459,"eighty":-1.664635,"marketCap":72959048},{"date":"2026-01-16","current":-1.62031,"twenty":-4.626115,"median":-4.109807,"eighty":-1.664635,"marketCap":70083290},{"date":"2026-01-23","current":-1.740972,"twenty":-4.605462,"median":-4.016872,"eighty":-1.646413,"marketCap":75302258},{"date":"2026-01-30","current":-1.803765,"twenty":-4.550733,"median":-3.972986,"eighty":-1.66168,"marketCap":78018252},{"date":"2026-02-06","current":-1.726197,"twenty":-4.505299,"median":-3.939426,"eighty":-1.666605,"marketCap":74663201},{"date":"2026-02-12","current":-1.72866,"twenty":-4.49394,"median":-3.91361,"eighty":-1.667098,"marketCap":74769711}],"updateTime":1771045848975},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610629353","title":"American Tungsten Announces Strong Initial Drill Results at IMA Mine in Idaho","url":"https://stock-news.laohu8.com/highlight/detail?id=2610629353","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610629353?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:39","pubTimestamp":1770734379,"startTime":"0","endTime":"0","summary":"Demesne Resources Ltd. ( ($TSE:TUNG) ) has shared an update. American Tungsten Corp. has reported initial underground drilling results from its Pha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/american-tungsten-announces-strong-initial-drill-results-at-ima-mine-in-idaho?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/american-tungsten-announces-strong-initial-drill-results-at-ima-mine-in-idaho?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4107","IMA","BK4117","BK4007","AFG"],"gpt_icon":0},{"id":"2610642341","title":"Press Release: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610642341","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610642341?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:00","pubTimestamp":1770724800,"startTime":"0","endTime":"0","summary":"Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership. Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis. Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe. \"Welcoming Ben to the Imagene team is the next step in executing our plans to create a focused, clinically excellent company. Ben's expertise in autoimmune and inflammatory diseases within and beyond medical dermatology, including his previous work on OX40 signaling inhibitors, is an incredible asset for our program. A recognized people leader, Ben will build and lead our clinical team, which will be essential as we focus on the execution of our Phase 2b ADAPTIVE trial in AD.\" commented Kristin Yarema, PhD, Chief Executive Officer of Imagene.\"Imagene has a compelling opportunity to make meaningful advances for pa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AD","IMA","BK4132","MLTX","PBIB","BK4139"],"gpt_icon":0},{"id":"2603081633","title":"American Tungsten Expands Underground Drilling at Historic IMA Mine in Idaho","url":"https://stock-news.laohu8.com/highlight/detail?id=2603081633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603081633?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:12","pubTimestamp":1768317146,"startTime":"0","endTime":"0","summary":"Demesne Resources Ltd. ( ($TSE:TUNG) ) has issued an update. American Tungsten Corp. has advanced its underground drill program at the IMA Mine in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/american-tungsten-expands-underground-drilling-at-historic-ima-mine-in-idaho?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/american-tungsten-expands-underground-drilling-at-historic-ima-mine-in-idaho?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4107","AFG","BK4007","BK4117","IMA"],"gpt_icon":0},{"id":"2600170875","title":"Joseph Slattery Spends US$96k On ImageneBio Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2600170875","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600170875?lang=en_us&edition=fundamental","pubTime":"2025-12-31 19:05","pubTimestamp":1767179133,"startTime":"0","endTime":"0","summary":"Even if it's not a huge purchase, we think it was good to see that Joseph Slattery, the Director of ImageneBio, Inc...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ima/imagenebio/news/joseph-slattery-spends-us96k-on-imagenebio-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ima/imagenebio/news/joseph-slattery-spends-us96k-on-imagenebio-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","IMA"],"gpt_icon":0},{"id":"2595186753","title":"Director Joseph P. Slattery Reports Acquisition of ImageneBio Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595186753","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595186753?lang=en_us&edition=fundamental","pubTime":"2025-12-30 05:47","pubTimestamp":1767044830,"startTime":"0","endTime":"0","summary":"Joseph P. Slattery, Director at ImageneBio Inc., has reported the acquisition of common shares of ImageneBio Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImageneBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDLWcnls:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Joseph P. Slattery Reports Acquisition of ImageneBio Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMA","BK4007"],"gpt_icon":0},{"id":"2592189181","title":"ImageneBio Chief Medical Officer Yufang Lu Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2592189181","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592189181?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:06","pubTimestamp":1766091995,"startTime":"0","endTime":"0","summary":"ImageneBio Inc. announced that Chief Medical Officer Yufang Lu, M.D., Ph.D., has resigned effective December 31, 2025. The company is searching for a replacement, and Dr. Lu will provide transition advisory services following her departure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImageneBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL6f13RF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMA","BK4007"],"gpt_icon":0},{"id":"2586419512","title":"Top Korean Securities Firms' Drive Toward Risky Corporate Financing a Capitalization Risk, S&P Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2586419512","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586419512?lang=en_us&edition=fundamental","pubTime":"2025-11-27 18:31","pubTimestamp":1764239476,"startTime":"0","endTime":"0","summary":"An abrupt jump in corporate financing exposure could hurt the capitalization of the two biggest Korean securities firms, S&P Global Ratings said in a Thursday release.Mirae Asset Securities  and Korea Investment & Securities recently received a green light to market the newly introduced investment management account  products, subjecting them to risky corporate financing or \"venturous financing,\" S&P said.Credit analyst Sunghyun Park said the securities firms have enough buffers against a moderate rise in risky equities or funds, but an aggressive increase could pressure their ratings.Risk-adjusted capital ratios that are persistently under 7% could prompt the rating agency to lower the ratings, credit analyst Daehyun Kim said.A 40% investment of IMA-raised funds into equities or funds could reduce the  RAC ratios to about 7.4% for Mirae and 7.1% for Korea Investment & Securities from 9.1% and 9.3% at end-2024, S&P said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMA.AU","IMA","BK7095","BK4007"],"gpt_icon":0},{"id":"2586247934","title":"ImageneBio Coverage Assumed by Wedbush at Underperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2586247934","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586247934?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:13","pubTimestamp":1764079980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 09:13 ET (14:13 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMA","BK4007"],"gpt_icon":0},{"id":"2586847476","title":"ImageneBio assumed at Underperform from Neutral at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2586847476","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586847476?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:30","pubTimestamp":1764077449,"startTime":"0","endTime":"0","summary":"Wedbush analyst Martin Fan downgraded ImageneBio (IMA) to Underperform from Neutral with a price target of $2, down from $23, while assuming covera...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/imagenebio-assumed-at-underperform-from-neutral-at-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/imagenebio-assumed-at-underperform-from-neutral-at-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IMA"],"gpt_icon":0},{"id":"2586847884","title":"Imagenebio Inc : Wedbush Assumes Coverage With Underperform Rating; Price Target $2","url":"https://stock-news.laohu8.com/highlight/detail?id=2586847884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586847884?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:25","pubTimestamp":1764073531,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMA","BK4007"],"gpt_icon":0},{"id":"2586420447","title":"Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2586420447","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586420447?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:17","pubTimestamp":1764073027,"startTime":"0","endTime":"0","summary":"Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","BK4504","IMA","TGT","LU0823411888.USD","LU2237443622.USD","LU0310799852.SGD","LU1244550221.USD","BK4588","LU1244550494.USD","BK4007","LU2237443382.USD","BK4114","BK4155","BK4597","LU1267930490.SGD","LU0211328371.USD","LU2237443549.SGD","LU2237443978.SGD","LU1267930227.SGD","LU0211327993.USD","LU0128525689.USD","LU0052756011.USD","LU0310800965.SGD","BK4585","BK4596","LU1244550577.SGD","BK4533"],"gpt_icon":0},{"id":"2582375919","title":"ImageneBio Q3 EPS $(2.91) Misses $(1.28) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375919","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375919?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:17","pubTimestamp":1762949824,"startTime":"0","endTime":"0","summary":"ImageneBio (NASDAQ:IMA) reported quarterly losses of $(2.91) per share which missed the analyst consensus estimate of $(1.28) by 127.34 percent. This is a 12.79 percent decrease over losses of $(2.58) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48799303/imagenebio-q3-eps-2-91-misses-1-28-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","NVIW.SI","PSQ","TSYW.SI","USAW.SI",".IXIC","NQmain","USJW.SI","QLD","SQQQ","TQQQ","QID","IMA","BK4007"],"gpt_icon":0},{"id":"2582375438","title":"ImageneBio reports Q3 cash position of $142.6 million and increased R&D expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375438","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375438?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:15","pubTimestamp":1762949726,"startTime":"0","endTime":"0","summary":"ImageneBio Inc. reported a cash, cash equivalents, and marketable securities position of $142.6 million as of September 30, 2025, up from $12.1 million at December 31, 2024. The increase was primarily due to the completion of the merger with Ikena Oncology, Inc. and a concurrent $75.0 million private placement. Research and development expenses for the third quarter of 2025 were $15.6 million, up from $3.9 million in the same period of 2024, reflecting increased clinical trial expenses and non-cash stock-based compensation. General and administrative expenses rose to $11.0 million from $1.7 million, mainly due to higher stock-based compensation and professional services. Net loss for the quarter was $24.8 million, compared to $3.2 million in the prior year period, driven by additional operating and transaction costs related to the merger. The company also announced protocol amendments for the ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis, continued strong patient enro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLbfFHHc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","IKNA","BK4539","LU2210149790.SGD","LU2210150020.SGD","LU0314104364.USD","BK4585","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4007","IMA"],"gpt_icon":0},{"id":"2582375928","title":"Imagenebio Inc- Qtrly Loss per Share $2.91","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375928","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375928?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:15","pubTimestamp":1762949700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA3YJJ1S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IMA"],"gpt_icon":0},{"id":"2582375983","title":"Press Release: ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375983","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375983?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:15","pubTimestamp":1762949700,"startTime":"0","endTime":"0","summary":"$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025. Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis  announced to optimize study design in alignment with IMG-007's unique molecular attributes; strong patient enrollment continues. She continued, \"Our recent learnings reinforce our belief that the anti-OX40/OX40L class, with its unique mechanism, is on a promising path towards adoption in atopic dermatitis and other inflammatory and autoimmune indications. However, the peer data to date also highlight the need for a differentiated anti-OX40 treatment that is safe and can be administered at optimal doses for maximum efficacy. Both thoughtful study design and high-quality execution are essential to achieve success--we must 'sweat the small stuff.' We believe IMG-007 is the only anti-OX40 in mid- to late-stage clinical development that is non-T cell depleting and receptor-targeting, with a roughly 5-week half-li","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","AD","BK4132","BK4023","BK4595","IMA","BCG","ISDS","BK4007","TISI","BK4585","BK4600","STRK","BK4516","IMG","BK4212","BK4596","BK4588","BK4120"],"gpt_icon":1},{"id":"2582651332","title":"Demand for Income Remains Strong","url":"https://stock-news.laohu8.com/highlight/detail?id=2582651332","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582651332?lang=en_us&edition=fundamental","pubTime":"2025-11-11 14:46","pubTimestamp":1762843565,"startTime":"0","endTime":"0","summary":"In this edition of the IIR LMI Monthly Update we take a look at the key news in October. Demand for income focused strategies remains high with a number of vehicles raising capital while more vehicles look to increase the frequency of dividends to satisfy the demand for more regular income from investors.At the AGM on 21 October 2025, Pengana International Equities Limited  shareholders voted against the proposal to change the mandate to include global private credit exposure, removed four directors and voted in four directors nominated by WAM Strategic Value Limited .At the AGM on 9 October 2025, shareholders of WAM Alternative Assets Limited  voted against the resolution to terminate the Investment Management Agreement  and liquidate the Company. As a result of the vote, the IMA with Wilson Asset Management  Pty Limited has been extended to 13 October 2030.The discount to NTA has narrowed over the last 6 months, however there has been limited demand post the AGM. It will now be up to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/demand-for-income-remains-strong","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/demand-for-income-remains-strong","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["PIA.AU","IMA","WMX.AU","WAR.AU","DJW.AU","BK7037","WMA.AU","QRI.AU","BK4007","IMA.AU","AFI.AU","RYD.AU","MIR.AU","BK7095"],"gpt_icon":0},{"id":"2581323548","title":"ImageneBio Inc. Files Initial Beneficial Ownership Statement for Director Joseph P. Slattery","url":"https://stock-news.laohu8.com/highlight/detail?id=2581323548","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581323548?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:16","pubTimestamp":1762553780,"startTime":"0","endTime":"0","summary":"ImageneBio Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Joseph P. Slattery as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImageneBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 07, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL3v7L5L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMA","BK4007"],"gpt_icon":0},{"id":"2581887443","title":"ImageneBio Inc  expected to post a loss of $1.28 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581887443","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581887443?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:37","pubTimestamp":1762533425,"startTime":"0","endTime":"0","summary":"ImageneBio Inc  expected to post a loss of $1.28 a share - Earnings Preview ImageneBio Inc IMA.OQ IMA.O is expected to  show no change in quarterly revenue when it reports  results on November 10 (est","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ2DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IMA"],"gpt_icon":0},{"id":"2581209881","title":"Brazilian forestry industry intensifies investment in genetics, R&D, AI to address climate risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2581209881","media":"Fastmarkets","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581209881?lang=en_us&edition=fundamental","pubTime":"2025-11-07 13:00","pubTimestamp":1762491600,"startTime":"0","endTime":"0","summary":"Discover how AI innovation is reshaping the future of print and publishing, as revealed at the World Printers Summit 2025","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fastmarkets_highlight","url":"https://www.fastmarkets.com/insights/brazilian-forestry-industry-intensifies-investment-in-genetics-rd-ai-to-address-climate-risks/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fastmarkets.com/insights/brazilian-forestry-industry-intensifies-investment-in-genetics-rd-ai-to-address-climate-risks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fastmarkets_highlight","symbols":["IMA","BK4007"],"gpt_icon":0},{"id":"2581095006","title":"ImageneBio Inc. to Participate in Stifel Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095006","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095006?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:30","pubTimestamp":1762435824,"startTime":"0","endTime":"0","summary":"ImageneBio Inc., a clinical-stage biotechnology company developing therapeutics for immunological, autoimmune, and inflammatory diseases, will participate in a fireside chat at the 2025 Stifel Healthcare Conference on Thursday, November 13. The company is developing IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImageneBio Inc. published the original content used to generate this news brief via GlobeNewswire  on November 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLD71t6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4127","LU2210149790.SGD","BK4585","SF","IMA","LU2210150020.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}